Alternative splicing has been proposed as a key contributor to the genetic diversity observed in prostate tumors. Here, the authors focus on the clinically relevant consequences of alternative splicing in prostate cancer, and describe how cancer-specific splicing events may be exploited as novel biomarkers and therapeutic targets for individualized care of patients.
- Prabhakar Rajan
- David J. Elliott
- Hing Y. Leung
